Tradestie Institutional Equity Comparison Engine

MRNA vs PFE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PFE Overall Edge

PFE Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Pfizer Inc. (PFE) driven by superior Valuation, Growth & Margin, Options & Structure while MRNA counters with relative strength in Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus PFE at 9.3x Forward P/E and 29.1% operating margin (-0.4% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against PFE sits in CONSOLIDATION (58th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner PFE
MRNA 23.0x vs PFE 9.3x Fwd P/E
Growth & Margin Winner PFE
Op Margin -80.8% vs 29.1% ยท YoY +29.2% vs -0.4%
Momentum & Technical Winner MRNA
1Y +706.5% vs +10.1% ยท 52W Pos 67% vs 48%
Options & Structure Winner PFE
CONSOLIDATION (52nd %ile IV) vs CONSOLIDATION (58th %ile IV)
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
PFE NYSE
Pfizer Inc.
Pharmaceutical Preparations
$27.40
-0.51% 1D
Market Cap $157.0B
1M Return -9.93%
1Y Return +10.13%
Forward P/E 9.3x
Unified AI Score
49.4 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 68.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MRNA +706.45% PFE +10.13% Spread: +696.32 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period MRNA Revenue PFE Revenue MRNA Op. Margin PFE Op. Margin Margin Edge
FY2018 $140M $40.8B -306.0% 27.3% PFE
FY2019 $60M $40.9B -906.8% 39.2% PFE
FY2020 $800M $41.6B -95.0% 22.0% PFE
FY2021 $18.5B $73.6B 72.0% 29.8% MRNA
FY2022 $19.3B $91.8B 48.9% 34.2% MRNA
FY2023 $6.85B $50.9B -61.9% 4.2% PFE
FY2024 $3.24B $63.6B -121.9% 12.6% PFE
FY2025 $1.94B $62.6B -158.1% 12.4% PFE

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MRNA (3) vs PFE (7)
Institutional Metric MRNA PFE Criterion Row Winner
Market Capitalization Scale $80.7B $157.0B Larger Scale PFE
Trailing P/E Ratio Valuation 23.0x 39.3x Lower Multiple MRNA
Forward P/E Ratio Valuation 23.0x 9.3x Lower Multiple PFE
Revenue Growth (YoY) Growth +29.2% -0.4% Higher Growth MRNA
Operating Margin (TTM) Profitability -80.8% 29.1% Higher Margin PFE
Net Profit Margin Profitability -110.5% 6.3% Higher Margin PFE
Return on Equity (ROE) Capital Efficiency -34.5% 4.5% Higher ROE PFE
52-Week Range Position Momentum 67% ($22โ€“$281) 48% ($24โ€“$31) Stronger Trend MRNA
Beta / 30D Volatility Risk Regime 2.23ฮฒ ยท 78% Vol 0.18ฮฒ ยท 22% Vol Lower Realized Risk PFE
Unified Institutional Score Composite Signal 40.3 / 100 (SELL) 49.4 / 100 (HOLD) Higher Composite PFE

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MRNA vs PFE Buy Guide
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PFE CONSOLIDATION
56d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 58th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live PFE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MRNA nor PFE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.